{"pmid":32490733,"title":"Interleukin 6 polymorphisms as an indicator of COVID-19 severity in humans.","text":["Interleukin 6 polymorphisms as an indicator of COVID-19 severity in humans.","J Biomol Struct Dyn","Kirtipal, Nikhil","Bharadwaj, Shiv","32490733"],"journal":"J Biomol Struct Dyn","authors":["Kirtipal, Nikhil","Bharadwaj, Shiv"],"date":"2020-06-04T11:00:00Z","year":2020,"_id":"32490733","source":"PubMed","week":"202023|Jun 01 - Jun 07","doi":"10.1080/07391102.2020.1776640","topics":["Mechanism","Treatment"],"weight":1,"_version_":1668623433522479104,"score":9.490897,"similar":[{"pmid":32499314,"title":"Involvement of interleukin 6 in SARS-CoV-2 infection: siltuximab as a therapeutic option against COVID-19.","text":["Involvement of interleukin 6 in SARS-CoV-2 infection: siltuximab as a therapeutic option against COVID-19.","The aim of the study was to explore the involvement of interleukin 6 in SARS-CoV-2 infection, and to position the drug siltuximab in the management of severe forms of COVID-19. A bibliographic search was performed in Pubmed on the immune response to the disease, and in ClinicalTrials.gov on clinical trials with interleukin 6 blockers. Interleukin 6 is involved in the cytokine cascade, which originates as a consequence of an excessive immune response secondary to viral infection, aggravating lung affectation. Blockers of this cytokine (tocilizumab, sarilumab and siltuximab) are being studied as a strategy for treating the disease. Siltuximab is a monoclonal antibody indicated in Castleman's disease that could be administered in a single dose of 11 mg/kg in severe forms of COVID-19 that have increased interleukin 6.","Eur J Hosp Pharm","Palanques-Pastor, Tomas","Lopez-Briz, Eduardo","Poveda Andres, Jose Luis","32499314"],"abstract":["The aim of the study was to explore the involvement of interleukin 6 in SARS-CoV-2 infection, and to position the drug siltuximab in the management of severe forms of COVID-19. A bibliographic search was performed in Pubmed on the immune response to the disease, and in ClinicalTrials.gov on clinical trials with interleukin 6 blockers. Interleukin 6 is involved in the cytokine cascade, which originates as a consequence of an excessive immune response secondary to viral infection, aggravating lung affectation. Blockers of this cytokine (tocilizumab, sarilumab and siltuximab) are being studied as a strategy for treating the disease. Siltuximab is a monoclonal antibody indicated in Castleman's disease that could be administered in a single dose of 11 mg/kg in severe forms of COVID-19 that have increased interleukin 6."],"journal":"Eur J Hosp Pharm","authors":["Palanques-Pastor, Tomas","Lopez-Briz, Eduardo","Poveda Andres, Jose Luis"],"date":"2020-06-06T11:00:00Z","year":2020,"_id":"32499314","source":"PubMed","week":"202023|Jun 01 - Jun 07","doi":"10.1136/ejhpharm-2020-002322","keywords":["clinical pharmacy","hospital pharmacy education","immunology","infectious diseases","intensive & critical care"],"e_drugs":["siltuximab","sarilumab","tocilizumab"],"topics":["Treatment","Mechanism"],"weight":1,"_version_":1668890966289809409,"score":47.47681},{"pmid":32460534,"title":"C3 and ACE1 polymorphisms are more important confounders in the spread and outcome of COVID-19 in comparison with ABO polymorphism.","text":["C3 and ACE1 polymorphisms are more important confounders in the spread and outcome of COVID-19 in comparison with ABO polymorphism.","Eur J Prev Cardiol","Delanghe, Joris R","De Buyzere, Marc L","Speeckaert, Marijn M","32460534"],"journal":"Eur J Prev Cardiol","authors":["Delanghe, Joris R","De Buyzere, Marc L","Speeckaert, Marijn M"],"date":"2020-05-29T11:00:00Z","year":2020,"_id":"32460534","source":"PubMed","week":"202022|May 25 - May 31","doi":"10.1177/2047487320931305","topics":["Mechanism"],"weight":1,"_version_":1668079521479262208,"score":41.62691}]}